Prostatic hyperplasia (BPH) is one of the common diseases in middle-aged and elderly men, and its incidence is increasing with the aging of the global population. The incidence of prostate hyperplasia increases with age, but clinical symptoms are not always present when hyperplastic lesions are present. The incidence is higher in urban than in rural areas, and ethnic differences also affect the degree of hyperplasia. Currently, the common drugs used to treat BPH can be summarized into 3 major categories, namely 5α-reductase inhibitors, α1 receptor blockers and botanicals (including herbs). 1, 5α-reductase inhibitors At present, finasteride (trade name: Paulownia) and domestic erythromycin (trade name: Epilept) are commonly used in clinical practice. The clinical observation shows that long-term use of these drugs can shrink the enlarged prostate volume by 20%, which can reduce the risk of acute urinary retention and surgery by half, and these drugs are effective for patients with large prostate volume. It is a good idea to take a course of treatment for 3 months, which is characterized by a slow onset of action, although it can reduce the size of the prostate. The main common use of alpha 1 receptor blockers are phenobenzyme (trade name Zhulinamine), afuzosin (trade name Sangta), terazosin (trade name Gauteng), doxazosin gastrointestinal type controlled release tablets (trade name Cordova), tamsulosin hydrochloride (trade name Harle), napalmedil tablets, etc. The effect of these drugs is characterized by fast onset of action, some of which can appear in a few days of use, but cannot reduce the volume of the prostate. This is the first time I’ve ever seen a woman in the world who has been in a position to be a part of a family. The mechanism of action is not clear. It may be the result of the combined action of multiple pathways and multiple targets. This kind of drugs generally have a slower onset of action, such as prostaglandin, sennitone and a variety of proprietary Chinese medicines.